## AMENDMENTS TO THE SPECIFICATION

**Please replace the last paragraph at page 11 (bridging the first paragraph of page 12) of the present specification with the following amended paragraph:**

The HDAC-inhibiting compound for use in the invention is a compound inhibiting HDAC or a salt thereof. Specifically, it includes such as FK228 (FR901228) and its reduced form, depsipeptide compounds (Compounds A, B, and C) and their reduced forms, MS-27-275, Trichostatin A NVP-LAQ824 ((2E) -N-hydroxy-3- [4- ({ (2-hydroxyethyl) [2- (1H-indol-3-yl)ethyl]amino)methyl)phenyl]acrylamide), SAHA, Apicidin (cycle(N-O-methyl-L-tryptophanyl-L-isoleucinyl-D-pipecolinyl-L-2-amino-8-oxodecanoyl), butyric acid and its derivatives (Phenylbutyrate, Pivaloyloxymethyl butyrate, Valproic acid, *etc.*), CI-994 (N-acetyldinaline), Depudecin, Trapoxin and CHAP (cyclic hydroxyamic acid containing peptides), which are known to be HDAC-inhibiting compounds. These HDAC-inhibiting compounds are commercially available or obtainable using methods known by references. Preferred ones are FK228 and its reduced form, depsipeptide compounds (Compounds A, B, and C) and their reduced forms, MS-27-275, Trichostatin A, NVP-LAQ824, SAHA, Apicidin, Phenylbutyrate, and Valproic acid, and more preferred ones are FK228 and its reduced form, depsipeptide compounds (Compounds A, B, and C) and their reduced forms, MS-27-275, Trichostatin A, NVP-LAQ824, SAHA, and Apicidin. Additionally, derivatives of these compounds having a similar activity are also suitable as the HDAC-inhibiting compounds of the present invention.